Day: March 18, 2025

In obesity-associated cardiomyopathy (OAC), heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with congestive heart failure and sudden cardiac death predominant causes of death. Data showed that NLRP3 inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function. Data support the potential of ZyVersa’s Inflammasome ASC Inhibitor IC 100 as an effective treatment option for patients with obesity and its associated cardiovascular comorbidities.WESTON, Fla., March 18, 2025 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases,...

West Seneca, New York, March 18, 2025 (GLOBE NEWSWIRE) — Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or the “Company”), a U.S. based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors, today shares proactive business commentary and outlines key catalyst events projected for 2025. Corporate Valuation and Growth OutlookStock Valuation: Worksport Ltd. holds more than 170 registered and pending patents and trademarks, maintains $6 million cash on hand (as of March 3, 2025), and carries minimal debt (Debt-to-Asset Ratio of 0.32 as of December 31, 2024). The Company’s advanced U.S. manufacturing facility is designed to accommodate annual revenue streams of $100 million to $300 million, and total factory assets exceed current market capitalization. Management...

Press release_2024 Universal Registration Document available_18 03 25  PRESS RELEASE  March 18, 20252024 UNIVERSAL REGISTRATION DOCUMENT AVAILABLE Kering’s 2024 Universal Registration Document was filed with the French Financial Markets Authority (AMF) in the European Single Electronic Format (ESEF) on Tuesday, March 18, 2025, under the reference number D.25-0103. The document is publicly available under the current regulatory conditions and can be accessed on Kering’s website at www.kering.com, in both French and English, within the Finance / Regulated Information’ section. It is also available on the AMF website at www.amf-france.org/en in French. The Universal Registration Document includes the annual financial report, the report of the Board of Directors on corporate governance, the sustainability statements,...

TORONTO, March 18, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, invites interested parties to participate in a conference call with Aras Azadian, Chief Executive Officer, and also Phil Cardella, Chief Financial Officer, where Mr. Azadian and Mr. Cardella will discuss the Company’s Full Year 2024 financial results. The Company will file Full Year 2024 financial results after the close of market on March 31, 2025 and will host an earnings call at 8:30 am ET on April 1, 2025. Interested parties may join the earnings call by clicking below: CLICK TO REGISTER Please use Passcode 240829.About Avicanna: Avicanna is a commercial-stage international...

Utrecht, 18 March 2025 Aalberts today reports that it has repurchased 144,030 of its own shares in the period from 10 March 2025, up to and including 14 March 2025, for an amount of EUR 4,901,346, so at an average share price of EUR 34.03 This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be cancelled following repurchase. Up to and including 14 March 2025, a cumulative total of 274,192 shares was repurchased under the share buyback programme for a total consideration of EUR 9,182,170. Aalberts has engaged an intermediary to repurchase the Aalberts shares in the open market, during open and closed periods, independent of Aalberts. The...

Marimekko Corporation, Stock Exchange Release 18 March 2025 at 1.00 p.m. EET Marimekko’s annual report for 2024 is published Marimekko Corporation has published today Marimekko’s year 2024 publication, which includes the report of the Board of Directors, the consolidated financial statements, the parent company financial statements, the corporate governance statement and the remuneration report for 2024. The publication is available in English and Finnish in PDF format. The report of the Board of Directors includes for the first time the sustainability report, prepared in accordance with the Corporate Sustainability Reporting Directive (CSRD) and the European Sustainability Reporting Standards (ESRS) as well as the Finnish Accounting Act’s Chapter 7 on sustainability reporting. Authorized Sustainability Audit Firm KPMG Oy Ab has assured...